REGENXBIO (NASDAQ:RGNX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX) in a research note released on Wednesday morning,Benzinga reports. They currently have a $36.00 price objective on the biotechnology company’s stock.

Several other research firms also recently issued reports on RGNX. Chardan Capital reaffirmed a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research note on Wednesday, November 20th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 target price on shares of REGENXBIO in a research report on Wednesday, December 11th. Morgan Stanley reiterated an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Raymond James restated an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Stock Up 5.5 %

NASDAQ RGNX opened at $7.44 on Wednesday. The business has a 50 day moving average price of $8.87 and a 200 day moving average price of $10.54. REGENXBIO has a 1-year low of $6.56 and a 1-year high of $28.80.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Amalgamated Bank grew its position in shares of REGENXBIO by 9.9% in the second quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,227 shares during the period. FMR LLC boosted its holdings in REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares during the last quarter. Arizona State Retirement System grew its position in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 1,997 shares during the period. nVerses Capital LLC increased its stake in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.